Overview
Next-generation CAR-T cell therapies
MedTherapy leverages next generation technology with cutting-edge platform for manufacturing of affordable viral vectors and CAR T cell gene therapy products tailor made to meet the grade and scale of the partners.
Why MedTherapy?
TEAM
- Founded by the leading experts on cancer gene therapy from Harvard University and former Novartis experts;
- Partnership with global experts in cell, gene and immunotherapies from prestigious private and public institutions from US, Europe and Asia;
TECHNOLOGY
- Full-service, end-to-end, integrated, CAR-T cell gene therapy biotech Global manufacturing facilities;
- In-house global scale GMP manufacturing facilities, and, in-house large scale virus vector manufacturing facilities
- Proprietary manufacturing processes and platform for cell, gene and immunotherapies;
- One of the most advanced, brand new, state of art futuristic 21st century manufacturing facilities for cell, gene and immunotherapies;
- One of the shortest manufacturing time for CAR-T cell therapies;
RISK MANAGEMENT
- One of the shortest time from investment to revenue;
- One of the most de-risked CAR-T cell therapy biotech companies due to parallel business strategies and business units;
- Not predicated upon the vagaries of unpredictable and unsuccessful clinical trials;
- One of the most cost-effective manufacturers in the world for cell, gene and immunotherapies;
- Globally renowned lead investor;
- Business model with one of the highest and fastest Return on Investment (ROI).
Investor FAQ's
What is the area of operation of MedTherapy Biotech?
MedTherapy Biotech is an end to end, integrated Cancer Cell and Gene Therapy Company, with manufacturing sites across the globe. Our primary focus is the CAR T-cell manufacturing, Viral vector manufacturing and Services.
